Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Sanofi is paying $100 million upfront for an artificial intelligence-driven drug discovery deal with Exscientia that could be worth up to $5.3 billion, the…
Sanofi and U.K.-based Exscientia are extending their AI-drug-discovery partnership in a deal worth up to $5.3 billion to develop as many as 15 small-molecule…
Exscientia is restructuring and cutting roughly a quarter of its workforce as it prioritizes its highest-conviction wholly-owned oncology programs and slows…
Source summaries from our enrichment pipeline; follow links for originals.
All 13 sources with sentiment breakdown →
Sanofi and Exscientia announced a strategic research collaboration and license agreement on January 7, 2022 to develop up to 15 novel small molecule candidates across oncology and immunology, leveraging Exscientia's end-to-end AI-driven platform using actual patient samples. Exscientia received $100M upfront, with up to ~$5.2B in additional milestones plus tiered royalties. Since then the relationship has materially evolved: Exscientia plc was acquired by Recursion Pharmaceuticals (Nasdaq: RXRX) in an all-stock business combination completed November 20, 2024 (Exscientia became a wholly owned subsidiary and its EXAI ADSs were delisted from Nasdaq), so the Sanofi collaboration is now executed by Recursion. The partnership was not terminated and continues to advance: as of Q2 2025, Recursion reported a multi-target collaboration for up to 15 best-in-class or first-in-class programs across oncology and immunology with $130 million in upfront and milestone payments achieved to date (including a $7M immunology milestone in 2Q 2025), with each program carrying potential for over $300 million in additional milestone payments.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Sanofi SA / Exscientia plc (this deal) | 2022 | $5.3B | — |
| Sanofi SA / Regeneron Pharmaceuticals, Inc. | 2007 | $1.0B | 97 |
| Sanofi SA / Synthelabo S.A. | 1998 | $11.0B | 84 |
| Sanofi SA / Genzyme Corporation | 2011 | $20.1B | 84 |
| Sanofi SA / Amunix Pharmaceuticals Inc. | 2021 | $1.2B | 76 |
| Sanofi SA / Genzyme Corporation | 2010 | $18.5B | 75 |
| Sanofi SA / Translate Bio Inc. | 2018 | $805M | 73 |
← Browse all deals · How we score deals
More: 2022 deals · Sanofi SA deals · Immunology deals